Compare Davita Inc (DVA) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs HSBC Holdings plc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while HSBC Holdings plc trades at $92.61 (market cap $311.92B). The key difference: HSBC Holdings plc is far larger — about 27.6× Davita Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and HSBC Holdings plc for 36 Days on average.
| DVA | HSBC | |
|---|---|---|
Market Cap | $11.29B | $311.92B |
Volume | 582,204 | 3,546,658 |
Sector | Health | Financials |
52-Week High | $240.96 | $107.86 |
52-Week Low | $103.87 | $65.67 |
Typical Hold Time | 113 Days | 36 Days |
Enterprise Value | $24.01B | $222.19B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
HSBC trades at $93.71, down 3.97% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and recent earnings beats in two of the last three quarters. Recent developments include expansion in technology banking and wealth management services, while analyst consensus leans toward Hold with 52.38% of ratings.
The outlook remains mixed with strong profitability metrics offset by bearish technical indicators and negative net cash flow. Key opportunities include wealth management growth and strategic hires, while risks involve CFO transition and competitive pressures. The stock's valuation appears reasonable but requires monitoring of cash flow trends and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
